{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:24:19Z","timestamp":1790036659239,"version":"4.0.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy of many non-surgical treatments for Peyronie\u2019s disease is unclear. This systematic review aims to critically assess the currently available options and provide a recommendation for treatment based on this. A systematic literature search utilising the Medline (Pubmed), Embase, global health and Cochrane library databases was conducted up to May 2021. All randomised controlled trials assessing non-surgical treatment modalities for Peyronie\u2019s Disease were included. Individual study risk of bias was evaluated using the Cochrane tool and GRADE was used to assess evidence strength. Outcome measures were the change in penile curvature (degrees), plaque size (volume or size), International Index of Erectile Function score, pain scores and change in penile length. Prospero registration number: CRD42017064618. Amongst the 5549 articles identified, 41 studies (42 reports) were included. Seven different oral treatment options including vitamin E supplementation showed evidence for improving outcomes such as penile curvature and plaque size. Of the intralesional treatments, Collagenase Clostridium Histolyticum showed evidence for improving penile curvature (Range: 16.3\u201317 degrees, moderate level certainty of evidence). Intralesional Interferon demonstrated some improvement in curvature (Range: 12\u201313.5 degrees), plaque size (Range: 1.67\u20132.2\u2009cm<jats:sup>2<\/jats:sup>) and pain, whilst intralesional calcium channel blockers such as Verapamil showed variable evidence for changes in the plaque size and pain. Extracorporeal Shockwave Therapy consistently demonstrated evidence for improving penile pain in stable disease, and two mechanical traction devices improved curvature. Iontophoresis, topical medications, and combination therapies did not demonstrate any consistent improvements in outcome measures. Intralesional options demonstrate the best potential. Overall, results varied with few high-quality randomised trials present.<\/jats:p>","DOI":"10.1038\/s41443-022-00633-w","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T14:03:32Z","timestamp":1666793012000},"page":"523-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A systematic review of non-surgical management in Peyronie\u02bcs disease"],"prefix":"10.1038","volume":"35","author":[{"given":"Sulaiman","family":"Hayat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-922X","authenticated-orcid":false,"given":"Oliver","family":"Brunckhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain M","family":"Alnajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7499-7227","authenticated-orcid":false,"given":"Onur Omer","family":"Cakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Muneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5135-9211","authenticated-orcid":false,"given":"Kamran","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"633_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie\u2019s disease: AUA guideline. J Urol. 2015;194:745\u201353.","journal-title":"J Urol."},{"key":"633_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1743-6109.2012.02999.x","volume":"10","author":"CJ Nelson","year":"2013","unstructured":"Nelson CJ, Mulhall JP. Psychological impact of Peyronie\u2019s disease: a review. J Sex Med. 2013;10:653\u201360.","journal-title":"J Sex Med."},{"key":"633_CR3","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1111\/j.1743-6109.2008.00949.x","volume":"5","author":"JF Smith","year":"2008","unstructured":"Smith JF, Walsh TJ, Conti SL, Turek P, Lue T. Risk factors for emotional and relationship problems in Peyronie\u2019s disease. J Sex Med. 2008;5:2179\u201384.","journal-title":"J Sex Med."},{"key":"633_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/sj.ijir.3900863","volume":"14","author":"F Sommer","year":"2002","unstructured":"Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, et al. Epidemiology of Peyronie\u2019s disease. Int J Impot Res. 2002;14:379\u201383.","journal-title":"Int J Impot Res."},{"key":"633_CR5","doi-asserted-by":"crossref","unstructured":"Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie\u2019s disease in the United States: a population-based study. PLoS One. 2016;11:e0150157.","DOI":"10.1371\/journal.pone.0150157"},{"key":"633_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/sj.ijir.3901518","volume":"19","author":"M Arafa","year":"2007","unstructured":"Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie\u2019s disease in diabetic patients with erectile dysfunction. Int J Impot Res. 2007;19:213\u20137.","journal-title":"Int J Impot Res."},{"key":"633_CR7","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/j.1743-6109.2009.01655.x","volume":"7","author":"R Tal","year":"2010","unstructured":"Tal R, Heck M, Teloken P, Siegrist T, Nelson CJ, Mulhall JP. Peyronie\u2019s disease following radical prostatectomy: incidence and predictors. J Sex Med. 2010;7:1254\u201361.","journal-title":"J Sex Med."},{"key":"633_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.eururo.2007.06.036","volume":"53","author":"SM Haag","year":"2008","unstructured":"Haag SM, Hauck EW, Eickelberg O, Szardening-Kirchner C, Diemer T, Weidner W. Investigation of the antifibrotic effect of IFN-\u03b3 on fibroblasts in a cell culture model of Peyronie\u2019s disease. Eur Urol. 2008;53:425\u201331.","journal-title":"Eur Urol."},{"key":"633_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/ncpuro0201","volume":"2","author":"NF Gonzalez-Cadavid","year":"2005","unstructured":"Gonzalez-Cadavid NF, Rajfer J. Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie\u2019s disease. Nat Clin Pr Urol. 2005;2:291\u20137.","journal-title":"Nat Clin Pr Urol."},{"key":"633_CR10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ."},{"key":"633_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01542-z","volume":"10","author":"ML Rethlefsen","year":"2021","unstructured":"Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10:39.","journal-title":"Syst Rev."},{"key":"633_CR12","unstructured":"Innovation VH Covidence systematic review software. Melbourne, Australia. 2022. www.covidence.org."},{"key":"633_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","volume":"49","author":"RC Rosen","year":"1997","unstructured":"Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822\u201330.","journal-title":"Urology."},{"key":"633_CR14","doi-asserted-by":"crossref","unstructured":"Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890.","DOI":"10.1136\/bmj.l6890"},{"key":"633_CR15","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.","journal-title":"BMJ"},{"key":"633_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol."},{"key":"633_CR17","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","volume":"178","author":"MR Safarinejad","year":"2007","unstructured":"Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of Vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178:1398\u2013403.","journal-title":"J Urol."},{"key":"633_CR18","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","volume":"91","author":"RM Prieto Castro","year":"2003","unstructured":"Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie\u2019s disease. BJU Int. 2003;91:522\u20134.","journal-title":"BJU Int."},{"key":"633_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","volume":"1","author":"G Paulis","year":"2013","unstructured":"Paulis G, Brancato T, D\u2019Ascenzo R, De Giorgio G, Nupieri P, Orsolini G, et al. Efficacy of vitamin E in the conservative treatment of Peyronie\u2019s disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1:120\u20138.","journal-title":"Andrology."},{"key":"633_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/1871528111312010009","volume":"12","author":"G Paulis","year":"2013","unstructured":"Paulis G, Cavallini G, Brancato T, Alvaro R. Peironimev-Plus(R) in the treatment of chronic inflammation of tunica albuginea (Peyronie\u2019s disease). results of a controlled study. Inflamm Allergy Drug Targets. 2013;12:61\u20137.","journal-title":"Inflamm Allergy Drug Targets."},{"key":"633_CR21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","volume":"162","author":"C Teloken","year":"1999","unstructured":"Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease. J Urol. 1999;162:2003\u20135.","journal-title":"J Urol."},{"key":"633_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2340\/00015555721518","volume":"72","author":"MR Griffiths","year":"1992","unstructured":"Griffiths MR, Priestley GC. A comparison of morphoea and lichen sclerosus et atrophicus in vitro: the effects of para-aminobenzoate on skin fibroblasts. Acta Derm Venereol. 1992;72:15\u20138.","journal-title":"Acta Derm Venereol."},{"key":"633_CR23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","volume":"47","author":"W Weidner","year":"2005","unstructured":"Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA\u2122) in the treatment of Peyronie\u2019s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47:530\u20136.","journal-title":"Eur Urol."},{"key":"633_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","volume":"97","author":"MG Ferrini","year":"2006","unstructured":"Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie\u2019s disease. BJU Int. 2006;97:625\u201333.","journal-title":"BJU Int."},{"key":"633_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","volume":"183","author":"U Ozturk","year":"2014","unstructured":"Ozturk U, Yesil S, Goktug HN, Gucuk A, Tuygun C, Sener NC, et al. Effects of sildenafil treatment on patients with Peyronie\u2019s disease and erectile dysfunction. Ir J Med Sci. 2014;183:449\u201353.","journal-title":"Ir J Med Sci."},{"key":"633_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","volume":"16","author":"MR Safarinejad","year":"2004","unstructured":"Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie\u2019s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16:238\u201343.","journal-title":"Int J Impot Res."},{"key":"633_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","volume":"88","author":"G Biagiotti","year":"2001","unstructured":"Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie\u2019s disease: a preliminary report. BJU Int. 2001;88:63\u20137.","journal-title":"BJU Int."},{"key":"633_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/ijir.2010.20","volume":"22","author":"MR Safarinejad","year":"2010","unstructured":"Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie\u2019s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010;22:298\u2013309.","journal-title":"Int J Impot Res."},{"key":"633_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199\u2013207.","journal-title":"J Urol."},{"key":"633_CR30","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","volume":"187","author":"M Gelbard","year":"2012","unstructured":"Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187:2268\u201374.","journal-title":"J Urol."},{"key":"633_CR31","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","volume":"116","author":"LI Lipshultz","year":"2015","unstructured":"Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116:650\u20136.","journal-title":"BJU Int."},{"key":"633_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/00365599109024539","volume":"25","author":"MR Duncan","year":"1991","unstructured":"Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie\u2019s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25:89\u201394.","journal-title":"Scand J Urol Nephrol."},{"key":"633_CR33","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"WJG Hellstrom","year":"2006","unstructured":"Hellstrom WJG, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon \u03b1-2b for minimally invasive treatment for Peyronie\u2019s disease. J Urol. 2006;176:394\u20138.","journal-title":"J Urol."},{"key":"633_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1743-6109.2005.00110.x","volume":"2","author":"M Kendirci","year":"2005","unstructured":"Kendirci M, Usta MF, Matern RV, Nowfar S, Sikka SC, Hellstrom WJ. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie\u2019s disease. J Sex Med. 2005;2:709\u201315.","journal-title":"J Sex Med."},{"key":"633_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/sj.ijir.3900874","volume":"14","author":"JP Mulhall","year":"2002","unstructured":"Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie\u2019s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res. 2002;14:397\u2013405.","journal-title":"Int J Impot Res."},{"key":"633_CR36","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1073\/pnas.93.11.5478","volume":"93","author":"M Roth","year":"1996","unstructured":"Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA. 1996;93:5478\u201382.","journal-title":"Proc Natl Acad Sci USA."},{"key":"633_CR37","first-page":"34","volume":"15","author":"R Sharma","year":"2016","unstructured":"Sharma R, Gupta R, Choudhary A, Dey RK, Maity D, Basu S, et al. Effectiveness of intralesional verapamil versus saline for treatment of Peyronie\u2019s disease - a randomized single blind, placebo controlled study. IOSR-JDMS. 2016;15:34\u20137.","journal-title":"IOSR-JDMS."},{"key":"633_CR38","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1111\/j.1743-6109.2010.01924.x","volume":"7","author":"J Soh","year":"2010","unstructured":"Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochiai A, Naitoh Y, et al. Nicardipine vs. saline injection as treatment for Peyronie\u2019s disease: a prospective, randomized, single-blind trial. J Sex Med. 2010;7:3743\u20139.","journal-title":"J Sex Med."},{"key":"633_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","volume":"41","author":"M Shirazi","year":"2009","unstructured":"Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41:467\u201371.","journal-title":"Int Urol Nephrol."},{"key":"633_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5539\/gjhs.v6n7p23","volume":"6","author":"M Alizadeh","year":"2014","unstructured":"Alizadeh M, Karimi F, Fallah MR. Evaluation of verapamil efficacy in Peyronie\u2019s disease comparing with pentoxifylline. Glob J Health Sci. 2014;6:23\u201330.","journal-title":"Glob J Health Sci."},{"key":"633_CR41","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s11255-015-1074-1","volume":"47","author":"R Gennaro","year":"2015","unstructured":"Gennaro R, Barletta D, Paulis G. Intralesional hyaluronic acid: an innovative treatment for Peyronie\u2019s disease. Int Urol Nephrol. 2015;47:1595\u2013602.","journal-title":"Int Urol Nephrol."},{"key":"633_CR42","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/andr.12368","volume":"5","author":"V Favilla","year":"2017","unstructured":"Favilla V, Russo GI, Zucchi A, Siracusa G, Privitera S, Cimino S, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie\u2019s disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017;5:771\u20135.","journal-title":"Andrology."},{"key":"633_CR43","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1590\/S1677-5538.IBJU.2015.0598","volume":"42","author":"L Toscano Jr.","year":"2016","unstructured":"Toscano L Jr., Rezende MV, Mello LF, Paulillo D, Glina S. A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie\u2019s Disease: a pilot study. Int Braz J Urol. 2016;42:1005\u20139.","journal-title":"Int Braz J Urol."},{"key":"633_CR44","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1046\/j.1464-410X.2000.00827.x","volume":"86","author":"J Husain","year":"2000","unstructured":"Husain J, Lynn NN, Jones DK, Collins GN, O\u2019Reilly PH. Extracorporeal shock wave therapy in the management of Peyronie\u2019s disease: initial experience. BJU Int. 2000;86:466\u20138.","journal-title":"BJU Int."},{"key":"633_CR45","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","volume":"106","author":"S Chitale","year":"2010","unstructured":"Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie\u2019s disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106:1352\u20136.","journal-title":"BJU Int."},{"key":"633_CR46","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/jsm.12275","volume":"10","author":"G Hatzichristodoulou","year":"2013","unstructured":"Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie\u2019s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10:2815\u201321.","journal-title":"J Sex Med."},{"key":"633_CR47","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","volume":"56","author":"A Palmieri","year":"2009","unstructured":"Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie\u2019s disease. Eur Urol. 2009;56:363\u201370.","journal-title":"Eur Urol."},{"key":"633_CR48","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41443-021-00447-2","volume":"34","author":"I Sokolakis","year":"2022","unstructured":"Sokolakis I, Pyrgidis N, Lahme S, Hatzichristodoulou G. Low-intensity shockwave therapy in Peyronie\u2019s disease: long-term results from a prospective, randomized, sham-controlled trial. Int J Impot Res. 2022;34:487\u201394.","journal-title":"Int J Impot Res."},{"key":"633_CR49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/j.1939-4640.2000.tb03279.x","volume":"21","author":"F Montorsi","year":"2000","unstructured":"Montorsi F, Salonia A, Guazzoni G, Barbieri L, Colombo R, Brausi M, et al. Transdermal electromotive multi-drug administration for Peyronie\u2019s disease: preliminary results. J Androl. 2000;21:85\u201390.","journal-title":"J Androl."},{"key":"633_CR50","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/01.ju.0000116450.82816.2c","volume":"171","author":"SM Di Stasi","year":"2004","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie\u2019s disease. J Urol. 2004;171:1605\u20138.","journal-title":"J Urol."},{"key":"633_CR51","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","volume":"177","author":"JM Greenfield","year":"2007","unstructured":"Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie\u2019s disease: a double-blind, placebo controlled trial. J Urol. 2007;177:972\u20135.","journal-title":"J Urol."},{"key":"633_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.2047-2927.2012.00018.x","volume":"1","author":"AR Mehrsai","year":"2013","unstructured":"Mehrsai AR, Namdari F, Salavati A, Dehghani S, Allameh F, Pourmand G. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie\u2019s disease. Andrology. 2013;1:129\u201332.","journal-title":"Andrology."},{"key":"633_CR53","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bju.14602","volume":"123","author":"I Moncada","year":"2019","unstructured":"Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, Martinez-Salamanca JI, et al. Penile traction therapy with the new device \u2018Penimaster PRO\u2019 is effective and safe in the stable phase of Peyronie\u2019s disease: a controlled multicentre study. BJU Int. 2019;123:694\u2013702.","journal-title":"BJU Int."},{"key":"633_CR54","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.jsxm.2020.10.003","volume":"17","author":"J Joseph","year":"2020","unstructured":"Joseph J, Ziegelmann MJ, Alom M, Savage J, K\u00f6hler TS, Trost L. Outcomes of RestoreX penile traction therapy in men with Peyronie\u2019s disease: results from open label and follow-up phases. J Sex Med. 2020;17:2462\u201371.","journal-title":"J Sex Med."},{"key":"633_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.15171\/jlms.2019.S7","volume":"10","author":"F Allameh","year":"2019","unstructured":"Allameh F, Razzaghi M, Rayegani SM, Fallah-Karkan M, Ranjbar A, Rahavian A, et al. Laser therapy for Peyronie\u2019s disease: a randomized control double-blind pilot study. J Lasers Med Sci. 2019;10:37\u201342.","journal-title":"J Lasers Med Sci."},{"key":"633_CR56","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","volume":"4","author":"WP Fitch 3rd","year":"2007","unstructured":"Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie\u2019s disease-a placebo-controlled pilot study. J Sex Med. 2007;4:477\u201384.","journal-title":"J Sex Med."},{"key":"633_CR57","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2005.04.011","volume":"48","author":"CR Riedl","year":"2005","unstructured":"Riedl CR, Sternig P, Gall\u00e9 G, Langmann F, Vcelar B, Vorauer K, et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie\u2019s disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol. 2005;48:656\u201361.","journal-title":"Eur Urol."},{"key":"633_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ijir.2015.22","volume":"28","author":"J Twidwell","year":"2016","unstructured":"Twidwell J, Levine L. Topical treatment for acute phase Peyronie\u2019s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int J Impot Res. 2016;28:41\u20135.","journal-title":"Int J Impot Res."},{"key":"633_CR59","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1046\/j.1464-410X.2002.02738.x","volume":"89","author":"G Cavallini","year":"2002","unstructured":"Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie\u2019s disease. BJU Int. 2002;89:895\u2013900.","journal-title":"BJU Int."},{"key":"633_CR60","first-page":"16","volume":"9","author":"C Maretti","year":"2020","unstructured":"Maretti C, Canale D. New therapeutical procedures of Peyronie\u2019s disease: transfer capacitive resistive energy in association with hydroelectrophoresis with verapamil. Int J Pharm Res Allied Sci.2020;9:16\u201323.","journal-title":"Int J Pharm Res Allied Sci."},{"key":"633_CR61","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4103\/0974-7796.152048","volume":"7","author":"L Dell\u2019Atti","year":"2015","unstructured":"Dell\u2019Atti L. Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie\u2019s disease. Urol Ann. 2015;7:345\u20139.","journal-title":"Urol Ann."},{"key":"633_CR62","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/and.12178","volume":"46","author":"V Favilla","year":"2014","unstructured":"Favilla V, Russo GI, Privitera S, Castelli T, Madonia M, La Vignera S, et al. Combination of intralesional verapamil and oral antioxidants for Peyronie\u2019s disease: a prospective, randomised controlled study. Andrologia. 2014;46:936\u201342.","journal-title":"Andrologia."},{"key":"633_CR63","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","volume":"67","author":"T Inal","year":"2006","unstructured":"Inal T, Tokatli Z, Akand M, \u00d6zdiler E, Yaman \u00d6. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie\u2019s disease: a randomized and prospective study. Urology. 2006;67:1038\u201342.","journal-title":"Urology."},{"key":"633_CR64","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","volume":"35","author":"A Palmieri","year":"2012","unstructured":"Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie\u2019s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35:190\u20135.","journal-title":"Int J Androl."},{"key":"633_CR65","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jsxm.2017.08.015","volume":"14","author":"DJ Ralph","year":"2017","unstructured":"Ralph DJ, Abdel Raheem A, Liu G. Treatment of Peyronie\u2019s disease with collagenase clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study. J Sex Med. 2017;14:1430\u20137.","journal-title":"J Sex Med."},{"key":"633_CR66","doi-asserted-by":"publisher","first-page":"526","DOI":"10.5534\/wjmh.200048","volume":"39","author":"T Cai","year":"2021","unstructured":"Cai T, Tiscione D, Favilla V, Puglisi M, Palumbo F, Zucchi A, et al. Oral administration and intralesional injection of hyaluronic acid versus intralesional injection alone in Peyronie\u2019s disease: results from a phase III study. World J Mens Health. 2021;39:526\u201332.","journal-title":"World J Mens Health."},{"key":"633_CR67","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jsxm.2018.12.011","volume":"16","author":"GI Russo","year":"2019","unstructured":"Russo GI, Cacciamani G, Cocci A, Kessler TM, Morgia G, Serefoglu EC, et al. Comparative effectiveness of intralesional therapy for Peyronie\u2019s disease in controlled clinical studies: a systematic review and network meta-analysis. J Sex Med. 2019;16:289\u201399.","journal-title":"J Sex Med."},{"key":"633_CR68","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.eururo.2018.07.005","volume":"74","author":"GI Russo","year":"2018","unstructured":"Russo GI, Milenkovic U, Hellstrom W, Levine LA, Ralph D, Albersen M. Clinical efficacy of injection and mechanical therapy for Peyronie\u2019s disease: a systematic review of the literature. Eur Urol. 2018;74:767\u201381.","journal-title":"Eur Urol."},{"key":"633_CR69","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1743-6109.2012.03003.x","volume":"10","author":"LA Levine","year":"2013","unstructured":"Levine LA, Burnett AL. Standard operating procedures for Peyronie\u2019s disease. J Sex Med. 2013;10:230\u201344.","journal-title":"J Sex Med."},{"key":"633_CR70","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","volume":"7","author":"D Ralph","year":"2010","unstructured":"Ralph D, Gonzalez-Cadavid N, Fau -, Mirone V, Mirone V, Fau -, et al. The management of Peyronie\u2019s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359\u201374.","journal-title":"J Sex Med."},{"key":"633_CR71","doi-asserted-by":"publisher","first-page":"381","DOI":"10.12688\/f1000research.20557.1","volume":"9","author":"A Babu","year":"2020","unstructured":"Babu A, Kayes O. Recent advances in managing Peyronie\u2019s disease. F1000Res. 2020;9:381.","journal-title":"F1000Res."},{"key":"633_CR72","unstructured":"Kerr R. FDA approves drug treatment for Peyronie\u2019s disease. 2013. http:\/\/urologytimes.modernmedicine.com\/urology-times\/content\/tags\/audrey-gassman\/fda-approves-drug-treatment-peyronie-s-disease."},{"key":"633_CR73","doi-asserted-by":"publisher","first-page":"539","DOI":"10.36740\/WLek202103129","volume":"74","author":"VA Chernylovskyi","year":"2021","unstructured":"Chernylovskyi VA, Krakhotkin DV, Chaikovskyi VP. Non-surgical treatment of peyronie\u2019s disease: a comprehensive review. Wiad Lek. 2021;74:539\u201345.","journal-title":"Wiad Lek."},{"key":"633_CR74","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.urology.2020.07.048","volume":"145","author":"HMT Nguyen","year":"2020","unstructured":"Nguyen HMT, Yousif A, Chung A, Virasoro R, Tapscott A, Ziegelmann M, et al. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute phase Peyronie\u2019s disease: a multi-institutional analysis. Urology. 2020;145:147\u201351.","journal-title":"Urology."},{"key":"633_CR75","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.urology.2020.01.035","volume":"139","author":"MJ Ziegelmann","year":"2020","unstructured":"Ziegelmann MJ, Heslop D, Houlihan M, Bajic P, Helo S, Trost L, et al. The influence of indentation deformity on outcomes with intralesional collagenase clostridium histolyticum monotherapy for Peyronie\u2019s disease. Urology. 2020;139:122\u201328.","journal-title":"Urology."},{"key":"633_CR76","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jsxm.2021.03.075","volume":"18","author":"M Alom","year":"2021","unstructured":"Alom M, Burgon H, Ziegelmann M, K\u00f6hler T, Helo S, Trost L. Continuing collagenase clostridium histolyticum injections among initial nonresponders results in significant curvature improvements in the majority of Peyronie\u2019s disease men. J Sex Med. 2021;18:1092\u201398.","journal-title":"J Sex Med."},{"key":"633_CR77","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ijir.2016.24","volume":"28","author":"L Gao","year":"2016","unstructured":"Gao L, Qian S, Tang Z, Li J, Yuan J. A meta-analysis of extracorporeal shock wave therapy for Peyronie\u2019s disease. Int J Impot Res. 2016;28:161\u20136.","journal-title":"Int J Impot Res."},{"key":"633_CR78","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5534\/wjmh.180100","volume":"37","author":"M Di Mauro","year":"2019","unstructured":"Di Mauro M, Russo GI, Della Camera PA, Di Maida F, Cito G, Mondaini N, et al. Extracorporeal shock wave therapy in Peyronie\u2019s disease: clinical efficacy and safety from a single-arm observational study. World J Mens Health. 2019;37:339\u201346.","journal-title":"World J Mens Health."},{"key":"633_CR79","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4103\/0974-7796.192100","volume":"8","author":"RK Shimpi","year":"2016","unstructured":"Shimpi RK, Jain RJ. Role of extracorporeal shock wave therapy in management of Peyronie\u2019s disease: a preliminary report. Urol Ann. 2016;8:409\u201317.","journal-title":"Urol Ann."},{"key":"633_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ijir.2011.45","volume":"24","author":"SM Larsen","year":"2011","unstructured":"Larsen SM, Levine LA. Review of non-surgical treatment options for Peyronie\u2019s disease. Int J Impot Res. 2011;24:1\u201310.","journal-title":"Int J Impot Res."},{"key":"633_CR81","first-page":"39","volume":"2","author":"LA Levine","year":"2013","unstructured":"Levine LA. Peyronie\u2019s disease: contemporary review of non-surgical treatment. Transl Androl Urol. 2013;2:39\u201344.","journal-title":"Transl Androl Urol."}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-022-00633-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-022-00633-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-022-00633-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T16:16:55Z","timestamp":1701274615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-022-00633-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["633"],"URL":"https:\/\/doi.org\/10.1038\/s41443-022-00633-w","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"7 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}